槐雪肾舒合剂治疗IgA肾病的临床研究  

A clinical study on oral solution of Huaixue Shenshu for treatment of patients with IgA nephropathy

作　　者：李燕林[1] 庞捷[1] 黄琳[1] 李锦山[1] 刘琳娜[1] 安海文[1] 杨文钦[1] 

机构地区：[1]广东省中山市中医院广州中医药大学附属中山市中医院,广东中山528400

出　　处：《中国中西医结合急救杂志》2015年第1期55-58,共4页Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care

基　　金：广东省建设中医药强省科研课题（20121078）

摘　　要：目的：观察槐雪肾舒合剂治疗IgA肾病的临床效果，并探讨其作用的机制。方法采用前瞻性研究，选择经病理诊断确诊为IgA肾病的患者40例，按随机数字表法分为治疗组和对照组，每组20例。两组均进行常规基础治疗，对照组在常规治疗基础上给予氯沙坦钾（科索亚）50∽100 mg；治疗组在常规治疗的同时给予槐雪肾舒合剂（药物组成：积雪草15 g，槐花20 g，旱莲草20 g，女贞子15 g，蝉蜕15 g，鹿衔草20 g，防风10 g，黄芪15 g，上药煎成200 mL分2次口服，每日1剂）；两组均3个月为1个疗程，共2个疗程。治疗后观察两组临床症状积分变化和临床疗效，于治疗前及治疗后3个月、6个月测定两组患者24 h尿蛋白、血肌酐（SCr）和白蛋白（Alb）。结果治疗前治疗组和对照组临床症状积分比较差异无统计学意义（分：18.42±5.41比19.95±6.25，P＞0.05）；治疗后两组均较治疗前明显降低，且以治疗组降低更显著（分：6.35±2.11比9.45±3.55， P＜0.05）。治疗组治疗后总有效率明显高于对照组〔75.0%（15/20）比40.0%（8/20），P＜0.05〕。两组治疗前24 h尿蛋白定量、SCr、Alb比较差异均无统计学意义（均P＞0.05）；随着治疗时间延长，两组24 h尿蛋白定量逐渐降低，Alb逐渐升高，治疗后6个月达峰值，且以治疗组的降低或升高更显著〔24 h尿蛋白（g）：0.71±0.58比1.31±0.55，Alb（g/L）：37.8±6.1比35.5±5.2，均P＜0.01〕；两组治疗前后SCr比较差异均无统计学意义（均P＞0.05）。结论槐雪肾舒合剂治疗IgA肾病疗效良好。Objective To observe the clinical therapeutic effect of oral solution of Huaixue Shenshu for treatment of patients with IgA nephropathy and explore its mechanism. Methods A prospective study was conducted. Forty patients with IgA nephropathy diagnosed by pathology were selected, and they were randomly divided into treatment group and control group, 20 cases in each group. The two groups were subjected to the routine treatment, and on this base, the control group also received cozaar 50-100 mg, while the treatment group additionally received oral solution of Huaixue Shenshu decoction （drug composition：Centellae herba 15 g, Sophorae Flos 20 g, Ecliptae Herba 20 g, Ligustri Lucidi Fructus 15 g, Cicadae Periostracum 15 g, Pyrolae Herba 20 g, Saposhnikoviae Radix 10 g, Astragali Radix 15 g, the above ingredients were immersed in water and boiled to form 200 mL decoction, as a dose, and then divided into two parts to take orally one of them each time, twice a day）. Both groups took two therapeutic courses in total, 3 months constituting one course. After treatment, the integral changes of clinical symptoms and clinical efficacy were observed, and before treatment and 3 months and 6 months after treatment, the 24-hour urine protein, serum creatinine （SCr）, and albumin （Alb） were measured in the two groups. Results Before treatment, there was no significant difference in integral of clinical symptoms between treatment group and control group （score： 18.42±5.41 vs. 19.95±6.25, P〉0.05）;after treatment, the integrals of two groups were significantly lower than those before treatment, and the degree of decrease in treatment group was more obvious （score： 6.35±2.11 vs. 9.45±3.55, P 〈 0.05）. After treatment the total effective rate in treatment group was significantly higher than that in control group [75.0% （15/20） vs. 40.0% （8/20）, P〈0.05]. Before treatment, the differences in 24-hour urinary protein, SCr and Alb were not significant between the two groups （all P 〉 0.05）; wit

关 键 词：槐雪肾舒合剂 IGA肾病 中西医结合疗法 

分 类 号：R692.31[医药卫生—泌尿科学]